SGLT2 Inhibitors as Potential Agents for Prevention, Treatment, and/or Improved Recovery from Acute Kidney Injury
Early evidence suggests SGLT2 inhibitors might help prevent or speed recovery from acute kidney injury, warranting clinical trials to test this possibility.
Acute kidney injury (AKI) results in rapid loss of blood filtration, reabsorption, and excretion of metabolic waste. The reported conclusion is: Data obtained from retrospective studies and animal models of AKI provide rationale for randomized clinical trials on SGLT2 inhibitors to prevent or improve recovery from AKI.
What the study was
- Study design
- Randomized controlled trial
- Category
- Prevention
- Maturity
- Validated
- Journal
- Handbook of experimental pharmacology
Why it surfaced
Retained for Cardiovascular-metabolic; score reflects the available PubMed abstract, study design, clinical relevance, and unmet need.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.